Drug Approved to Help Young Patients Battle a Rare Cancer
TUESDAY, Jan. 3, 2023 -- The U.S. Food and Drug Administration has approved the immunotherapy drug Tecentriq (atezolizumab) for use in patients with unresectable or metastatic alveolar soft part sarcoma (ASPS). The approval was granted following the...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
More News: Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | General Medicine | Immunotherapy | Sarcomas